BioCentury | Feb 2, 2021
Product Development
Feb. 2 Quick Takes: Immunovant tumbles as it pauses trial; plus BMS, Legend-J&J, Arcutis, Prothena, VBI, Travere, Concert and Adamas
...the PDE4 inhibitor in 2H21. Prothena gains on plans for Phase III AL amyloidosis studyShares of Prothena Corp. plc...